Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lupin & Natco Pharma Gets Final Approval for its ANDA for Bosentan Tablets
Details : Tracleer-Generic (bosentan) is an endothelin receptor antagonist small molecule drug candidate, which is indicated for the treatment of pulmonary arterial hypertension.
Product Name : Tracleer-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2025
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Natco Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study to Compare Bosentan 32 mg Dispersible Tablets Versus Tracleer® 32 mg Tablets
Details : Undisclosed
Product Name : Tracleer
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 03, 2024
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Tentative Approval from The USFDA for Bosentan Tablets for Oral Suspension
Details : Bosentan is a specific and competitive antagonist at endothelin receptor types ETA and ETB. It is developed for for the treatment of PAH in pediatric patients aged 3 years and older with idiopathic or congenial PAH to improve pulmonary vascular resistanc...
Product Name : Bosentan-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 15, 2023
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 24, 2019
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Instituto Universitario de Oftalmobiología Aplicada
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety of Bosentan in Type II Diabetic Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2019
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Instituto Universitario de Oftalmobiología Aplicada
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 24, 2015
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Endocrinology
Study Phase : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
ET-blockade and Exercise-induced Vascular Adaptations in T2DM
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 30, 2013
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Endocrinology
Highest Development Status : Phase IV
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Immunology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bosentan in Systemic Sclerosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2011
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Immunology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Persistent Pulmonary Hypertension of the Newborn
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2011
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Undisclosed
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 22, 2011
Lead Product(s) : Bosentan Hydrate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Undisclosed
Sponsor : Johnson & Johnson
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
